Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.

Cell mitochondria
Astellas' recent deals include the buyout of Nanna and its mitochondrial modulation expertise

Astellas Pharma, Inc., the multinational biopharma headquartered in Tokyo with multibillion-dollar operations in the US, was impacted by the same forces that buffeted many in the industry in 2020, including the global COVID-19 pandemic. The global health crisis delayed and, in some cases, halted ongoing projects at Astellas but it also offered new business opportunities and revealed novel ways to work and collaborate.

Astellas Pharma US Inc. President Percival Barretto-Ko oversees the company’s US operations from its base in Northbrook, IL. The...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.